Alexium’s new Phonon™ cooling technology to open up new markets

|

Published 04-AUG-2020 09:50 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Alexium International Group Limited (ASX:AJX) have increased 40% since mid-June, but there could be more upside to come with the company announcing today that it has developed a breakthrough technology for thermal management in textile- and foam-based consumer products.

The new PhononTM perpetual cooling technology enhances the rate of cooling by up to 200% over current products and more importantly the cooling never stops.

This breakthrough cooling technology is poised to disrupt markets by continually regulating and removing heat from consumers, creating a constantly comfortable experience.

The patent pending technology establishes a new standard for extended cooling performance, and from an operational perspective it opens up a host of new markets for Alexium, providing a new growth platform for the business.

Highlighting the potential to open up opportunities in new industries, applications are possible across consumables such as medical products, sporting goods, upholstery and outdoor apparel.

On this note, Alexium is seeking innovative and technology focus partners to expand new products applications.

This further complements the group’s other high profile products in Alexicool® and Alexiflam® which have applications in multiple markets.

Alexium’s performance chemicals and materials have advanced applications across the military, workwear and bedding products industries with a focus on flame retardancy and thermal management.

It was just in June that the group’s prototype foam mattresses using FR (flame retardant) socks treated with Alexiflam® NF passed flammability testing required by US federal safety standards.

New cooling technology provides AJX with a step change

This latest proprietary technology builds on years of research at Alexium and creates a new growth platform complementary to its Alexicool® phase change materials (PCM).

In contrast to PCM technology, which works by absorbing heat, PhononTM technology builds on this by counteracting the insulative effects of foams and textiles and constantly moving heat away from the consumer.

In brief, the hotter a person gets the more actively the product works to cool them.

It is also worth noting that PhononTM products provide enhanced cooling performance without any increased hazards to consumers or the environment.

Importantly, PhononTM products provide enhanced cooling at a significantly reduced weight relative to other cooling technologies.

In addition to its perpetual cooling properties, the technology also provides a wide range of benefits that consumers care about, including:

  • Adaptive/responsive cooling: The hotter a person gets, the more actively the PhononTM product works to cool them.
  • Non-flammable, non-toxic, and environmentally friendly product: PhononTM products provide enhanced cooling performance without any increased hazards to consumers or the environment
  • Lightweight: PhononTM products provide enhanced cooling at a significantly reduced weight relative to other cooling technologies.

New product to reinforce Alexium’s position in bedding market

Given the company’s established position in bedding markets, this industry is the initial target for commercial application of the new technology.

The PhononTM technology allows Alexium to significantly expand its offerings for total mattress cooling systems (TMCS) where a number of customer trials have proven the viability of this patent-pending, breakthrough technology platform.

The total addressable market in the US for cooling technologies in TMCS is estimated at US$60 million, with an additional US$25 million for top-of-bed applications.

Beyond bedding applications, this technology has comparable opportunities in other markets, including upholstery, medical products, sporting goods, and outdoor apparel/accessories.

Alexium TMCS

Highlighting the significance for the broader thermal management solutions industry, Alexium chief executive Bob Brookins said, "Cooling technologies have become a critical selling feature for premium mattress manufacturers over recent years and Alexium has garnered a deserved reputation for leading technical innovation and analytics via its Alexicool products.”

“Generally, technical innovation is incremental in nature and it is therefore particularly exciting to announce today a truly disruptive platform technology, one which we believe can change the narrative in relation to thermal management solutions not just for the global mattress industry but also for several other performance applications in consumer products."



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X